Barry Teater

T3D Therapeutics, a young Research Triangle Park company started with loan help from the North Carolina Biotechnology Center, has received approval from the Food and Drug Administration to test its lead drug candidate in patients with Alzheimer’s disease. “This is a significant milestone for our company,” said CEO John Didsbury. T3D plans to begin a phase two-a study this summer on the heels of the FDA’s approval of its Investigational New Drug application. The drug candidate, T3D-959, is a potential therapeutic for Alzheimer’s disease, designed to be given orally once a day. The molecule passed a phase one clinical...

Editor’s note: North Carolina’s Biotechnology Center and its partners are showcasing North Carolina at this week’s international BIO convention in Philadelphia. As part of that effort, the Biotech Center is publishing a series of articles over the next few days focusing on what’s happening in the Tar Heel state. Today’s feature is an overview: “NC: A Life Science Leader Poised for More Growth in 6 ‘SuperScieNCe’ Sector” written by Barry Teater. RESEARCH TRIANGLE PARK, N.C. – North Carolina’s life science sector grew four times faster than that of the rest of the nation over the last decade. Even so,...

Nine agricultural biotechnology companies from North Carolina and five other states will present their novel solutions to various problems at a one-day Ag Biotech Entrepreneurial Showcase event May 19 at the North Carolina Biotechnology Center. The companies are using innovative technology to produce specialty chemicals and pharmaceuticals in tobacco plants, regenerate tissues in injured horses, grow food under LED lights, wipe out bedbugs with a biopesticide, diagnose pathogens in livestock, control crop insects and produce enzymes. The annual Showcase is intended to drive commercialization by presenting investment-ready ag technologies to an audience of nearly 200 entrepreneurs, investors, tech scouts,...

Durham drug developer Innocrin Pharmaceuticals has closed on $28 million in Series D financing to test a new therapy for difficult prostate and breast cancers. Eshelman Ventures led the fully subscribed financing round and was joined by current investors Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners and A&B Equity Holdings. Innocrin is developing small-molecule inhibitors of CYP17 lyase, a key enzyme in certain cancers. Its leading drug candidate is VT-464, an oral medication intended to treat castration-resistant prostate cancer and hormonally dependent breast cancer. “The significant amount of capital provided by new and current investors is...